| DC8589 |
PAD4 inhibitor GSK484
Featured
|
GSK484 is a reversible inhibitor of PAD4 (IC50 = 50 nM) that binds to the low-calcium form of the enzyme. |
|
| DC10999 |
YW3-56 |
YW3-56 is a potent peptidylarginine deiminase (PAD) inhibitor with inhibitory activity against PAD2 (IC50=0.5-1 uM) and PAD4 (IC50=1-2 uM), inhibits U2OS cancer cell growth with IC50 of 2.5 uM. |
|
| DC47357 |
D-Cl-amidine hydrochloride |
D-Cl-amidine hydrochloride is a potent and highly selective PAD1 inhibitor. D-Cl-amidine is well-torelated with no significant toxicity. |
|
| DC70086 |
GSK-484
Featured
|
GSK-484 is a potent, highly selective and reversible protein arginine deiminase PAD4 inhibitor with IC50 of 80 nM in FP binding assay (0.2 mM Ca), 50 nM in PAD4 NH3 release inhibition assay. |
|
| DC72276 |
AFM-30a hydrochloride |
AFM-30a hydrochloride is a potent protein arginine deiminase 2 (PAD2) inhibitor and has excellent PAD2-selectivity. AFM-30a hydrochloride binds to PAD2 with an EC50 value of 9.5 μM. AFM-30a hydrochloride also inhibits H3 citrullination with an EC50 value of 0.4 μM. AFM-30a hydrochloride can be used for the research of certain cancers and a variety of autoimmune diseases including rheumatoid arthritis (RA), multiple sclerosis, lupus, and ulcerative colitis. |
|
| DC73779 |
GSK-199 |
GSK-199 is a potent, highly selective and reversible protein arginine deiminase PAD4 inhibitor with IC50 of 250 nM in FP binding assay (0.2 mM Ca), 200 nM in PAD4 NH3 release inhibition assay. |
|
| DC73780 |
JBI-589 |
JBI-589 (JBI589) is potent, selective, orally active PAD4 small molecule inhibitor, reduces CXCR2 expression and blocks neutrophil chemotaxis. |
|
| DC73781 |
ML325 |
ML325 (ML 325) is a potent, irreversible pan-protein arginine deiminase (PAD) inhibitor with IC50 of 70 nM, 200 nM 170 nM, and 240 nM for PAD1, 2, 3, and 4 in vitro respectively. |
|
